Symbols

EVGN

Evogene·NASDAQ

--(--)

EVGN fundamentals

EVGN Q4 2025 Earnings

Evogene (EVGN) released its earnings on Mar 5, 2026: revenue was 314.00K (YoY -80.51%), beat estimates; EPS was -0.61 (YoY -1116.67%), missed estimates.

Revenue / YoY

314.00K

-80.51%

EPS / YoY

-0.61

-1116.67%

Report date

Mar 5, 2026

EVGN Earnings Call Summary for Q4,2025

Strategic AI Focus: Evogene pivoted to ChemPass AI, generating novel molecules for pharma and ag chemicals, with Google Cloud collaborations enhancing precision.
Cost Efficiency: Operating expenses reduced by 37% YoY to $13.8M, enabling 1.5+ years of cash runway from $13M balance and subsidiary distributions.
Key Deals: $6.4M gain from Lavie Bio sale, BMC128 licensing with Lishan Pharmaceuticals, and 4+ pharma partnerships leveraging AI.
Growth Drivers: Upcoming collaborations in tech, pharma, and ag chemicals, with Google-like partnerships and Bayer/Corteva pipeline expansion.

Earnings

EPS

Revenue

Revenue & Expenses

EVGN has released its 2025 Q4 earnings report, with revenue of 314.00K, reflecting a YoY change of -79.65%, and net profit of -5.35M, showing a YoY change of -106980.00%. The Sankey diagram below clearly presents EVGN's revenue sources and cost distribution.

Key Indicators

Evogene (EVGN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Evogene (EVGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Evogene (EVGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Evogene (EVGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown